Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance

(2021) Kuba Retecki et al.   Cancers

Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer

(2020) Yuxiang Li et al.   CELLULAR IMMUNOLOGY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Landscape of Targeted Therapies in TNBC

(2020) Elena Vagia et al.   Cancers

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epidemiology of gynecologic cancers in China

(2018) Xiyi Jiang et al.   Journal of Gynecologic Oncology

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

(2015) Ibrahim Vedat Bayoglu et al.   BIOMEDICINE & PHARMACOTHERAPY

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

(2014) C. Alewine et al.   MOLECULAR CANCER THERAPEUTICS

Mesothelin, a novel immunotherapy target for triple negative breast cancer

(2012) Julia Tchou et al.   BREAST CANCER RESEARCH AND TREATMENT